Provention Bio Long Term Debt

Provention Bio (PRVB) currently reports a long-term debt of $24M as of December 2022. That compares with $590K in the prior-year period — up 3952.5% year over year. Use the charts on this page to explore Provention Bio's long-term debt history and peer comparisons.

Provention Bio's long-term debt increased from $590K to $24M — a 3952.5% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Provention Bio reported $24M in long-term debt as of December 2022. That compares with $590K in the prior-year period — up 3952.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $24M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Provention Bio, and consider following PRVB for alerts when major investors trade the stock.

Provention Bio is classified in the Healthcare sector. On long-term debt, it currently shows $24M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRVB with unrelated industries.